20170502 - AstraZeneca Breakfast Seminar |
Clinical implications of tumour-based BRC
Tracy Stockley, PhD, FCCMG, FACMGAssociate Director, Genome Diagnostics, Department of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto ON
Raymond Kim, MD, PhD, FRCPC, FCCMG, FACMGMedical Geneticist, Assistant Professor, Department of Medicine, University of Toronto, Toronto ON
Session 1:
Tumour-based BRCA1/2 mutation testing: The UHN genome diagnostics experience
At the end of this session participants will be able to:
• Provide an overview of germline versus tumour-based (germline and somatic) BRCA1/2 mutation testing; differences and caveats for somatic testing
• Relay the benefits of BRCA1/2 mutation tumour-based testing
• Outline UHN’s experience of implementing BRCA1/2 tumour testing, including discussion 3. of sample preparation, testing methodologies and somatic variant interpretation
Session 2:
Clinical integration of somatic and germline BRCA1/2 mutation testing: In future, how do they co-exist?
At the end of this session participants will be able to:
• Understand how the molecular basis of ovarian cancer, both germline and somatic mutations, may inform clinical treatment decisions
• Discuss potential clinical implementation models of somatic BRCA1/2 mutation testing, including test ordering and post-test counselling needs
• Relay challenges and opportunities to integrating tumour-based testing into current germline testing workflows
• Understand the role of the multidisciplinary team in enabling tumour-based BRCA1/2 mutation testing
Raymond Kim, MD, PhD, FRCPC, FCCMG, FACMGMedical Geneticist, Assistant Professor, Department of Medicine, University of Toronto, Toronto ON
Session 1:
Tumour-based BRCA1/2 mutation testing: The UHN genome diagnostics experience
At the end of this session participants will be able to:
• Provide an overview of germline versus tumour-based (germline and somatic) BRCA1/2 mutation testing; differences and caveats for somatic testing
• Relay the benefits of BRCA1/2 mutation tumour-based testing
• Outline UHN’s experience of implementing BRCA1/2 tumour testing, including discussion 3. of sample preparation, testing methodologies and somatic variant interpretation
Session 2:
Clinical integration of somatic and germline BRCA1/2 mutation testing: In future, how do they co-exist?
At the end of this session participants will be able to:
• Understand how the molecular basis of ovarian cancer, both germline and somatic mutations, may inform clinical treatment decisions
• Discuss potential clinical implementation models of somatic BRCA1/2 mutation testing, including test ordering and post-test counselling needs
• Relay challenges and opportunities to integrating tumour-based testing into current germline testing workflows
• Understand the role of the multidisciplinary team in enabling tumour-based BRCA1/2 mutation testing